Хондроитина сульфат: стратегии лечения остеоартрита

Abstract

Osteoarthritis (OA) is the most common among all musculoskeletal disorders, becoming the main cause of chronic pain, impaired static and dynamic function and disability among the elderly, and represents the main burden for public health worldwide. Modern pharmacological treatment methods of OA are focused on reducing the disease symptoms and the pain syndrome intensity. One method in this direction is the use of symptom-modifying slow-acting drugs, which have shown promising positive effects on pain and other OA symptoms. The article presents an overview of the main experimental and clinical studies, and meta-analyses devoted to the evaluation of chondroitin sulfate (CS) efficacy and safety as one of the most commonly prescribed drugs for the treatment of OA. Some studies are devoted to the assessment of structural changes in articular cartilage during CS and placebo therapy, while others focus on the dynamics of pain syndrome and the degree of functional insufficiency, and on the assessment of the incidence and time of delayed knee replacement. The place of CS in the structure of EULAR and ESCEO recommendations is considered. KEYWORDS: osteoarthritis, chondroitin sulfate, symptom-modifying slow-acting drugs, medial condyle, articular cartilage thickness, articular replacement. FOR CITATION: Alabut A.V. Chondroitin sulfate: treatment tactics in osteoarthritis. Russian Medical Inquiry. 2021;5(2):102–106. DOI: 10.32364/2587-6821-2021-5-2-102-106.